Fig. 1.

AD0157 reduces tumor growth and lymphangiogenesis in orthotopic mammary xenografts. a Evolution of tumor volumes in NOD/SCID mice implanted with MDA-MB-231/Luc+ cells and treated daily with vehicle (saline solution) or AD0157 (1.5 or 3 mg/kg) for 25 days, as indicated on top of the graph. Dashed line indicates the tumor volume (50 mm³) reached by tumors before drug treatment. Crosswise lines indicate the starting point for the statistical differences shown at right. b Mouse body weights before and during treatments. ns denotes no statistical differences between groups. c Representative in vivo bioluminescent signals of mice at the end of the treatment. d Quantification of tumor bioluminescent radiance. e Tumor weights at the end of the experiment. f Representative pictures of tumors harvested from mice treated with vehicle (control) or AD0157 (1.5 and 3 mg/kg). Each square represents a surface of 2.25 cm². g Representative histological sections showing human ki-67 (proliferation marker, in brown) and LYVE-1 (lymphatic vessel marker, in dark pink) stainings in mammary tumors. Scale bars represent 100 μm. h Quantification of human ki-67⁺ cell and lymphatic densities in histological sections of mammary tumors. Data are presented as mean ± s.e.m. One-way ANOVA significance test, followed by the Bonferroni test, was used to compare the tumor growth in the different conditions. The Wilcoxon-Mann-Whitney was applied for the rest of statistical tests. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 12 mice/group)